Medical News

RSS

Health Canada approves XIAFLEX for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Canada Inc. announced today that Auxilium was granted a Notice of Compliance (approval) by Health Canada for XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, first-in-class biologic for the treatment of Dupuytren's contracture in adults with a palpable cord in Canada.

9 Jul 2012

Stroke Telemedicine: An interview with Séamus Watson

Stroke is the third largest cause of death in England. (1) It is a condition that requires rapid assessment and treatment to reduce deaths, disability and the risk of having another stroke. (2)

9 Jul 2012

For states, High Court's Medicaid ruling creates choices, makes waves

States are responding to the court's decision in varying ways. Some interpretations are leading states to pare back their existing Medicaid programs, according to the Wall Street Journal. Others find themselves in limbo.

9 Jul 2012

Cook Medical receives FDA clearance for Evolution Colonic Controlled-Release Stent

The U.S. Food and Drug Administration (FDA) has granted Cook Medical 510(k) clearance for the Evolution Colonic Controlled-Release Stent, Cook announced today.

9 Jul 2012

Luminex to acquire molecular diagnostics company, GenturaDx

Luminex Corporation today announced a definitive agreement to acquire privately-held, GenturaDx, a molecular diagnostics company focused on making nucleic acid testing both affordable and practical for any laboratory. GenturaDx is in late stage development of a fully integrated, highly automated, real-time PCR system that employs a single-use cassette for true sample-to-answer workflow.

From Luminex 9 Jul 2012

NADDI lauds real-time, drug stop-sale system in North Carolina

The National Association of Drug Diversion Investigators (NADDI) – a nonprofit organization that facilitates cooperation between law enforcement, healthcare professionals, state regulatory agencies and pharmaceutical manufacturers in the prevention and investigation of drug diversion – today lauded the latest results achieved by the real-time, stop-sale system in North Carolina.

9 Jul 2012

Health law debate returns to center stage in House

With lawmakers returning to Washington this week after the July 4 break, Republican leaders in the House have scheduled a vote -- the 31st such attempt -- to repeal the health law. The effort is unexpected to get any traction in the Democrat-led Senate.

9 Jul 2012

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.

9 Jul 2012

Airline files suit to stop providing health benefits to current retirees

American Airlines and its parent company are suing to stop providing health care and life insurance benefits to current retirees. AMR Corp. and American filed the lawsuit Friday as part of their bankruptcy case in federal court in New York.

9 Jul 2012

Regnite to treat primary restless legs syndrome launched in Japan

Astellas Pharma Inc. and XenoPort, Inc. announced today that Regnite (gabapentin enacarbil) Extended-Release Tablets will be launched in Japan on July 10, 2012. Regnite is approved in Japan for the treatment of moderate-to-severe primary restless legs syndrome (RLS).

9 Jul 2012

Acusphere completes MAA dossier for Imagify to detect CAD

Acusphere, Inc. today announced that it had completed the Marketing Authorisation Application dossier for its lead product candidate, Imagify (Perflubutane Polymer Microspheres) for Injectable Suspension, and is now starting the process of filing the MAA dossier with the European Medicines Agency to support the regulatory review of Imagify in the European Union.

9 Jul 2012

Researchers use metal complexes to modify peptide hormones

Researchers at the RUB and from Berkeley have used metal complexes to modify peptide hormones. In the Journal of the American Chemical Society, they report for the first time on the three-dimensional structure of the resulting metal-peptide compounds.

9 Jul 2012

Consumer Reports investigates hospital safety

The magazine offers its rankings of the safest and most dangerous hospitals based on six criteria.

9 Jul 2012

Novel system to treat hair loss receives CE Mark approval

Restoration Robotics, Inc., a privately-held medical device company, today announced its revolutionary ARTAS System received CE Mark Certificate to market in the European Union. The ARTAS System is the first physician controlled, computer assisted technology that allows harvesting individual follicular units directly from the scalp.

9 Jul 2012

KannaLife enters exclusive license with NIH-OTT for patent regarding cannabinoids

KannaLife Sciences, Inc. Signs Exclusive License Agreement With National Institutes of Health – Office of Technology Transfer for the Commercialization of U.S. Patent 6,630,507, "Cannabinoids as Antioxidants and Neuroprotectants".

9 Jul 2012

Spacelabs receives FDA 510(k) clearance for Blease900 Ventilator

Spacelabs Healthcare today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for the Blease900 Ventilator - an integral component of its BleaseFocus anesthesia system - paving the way for launch of the new BleaseFocus anesthesia system to healthcare facilities in the United States.

9 Jul 2012

Nurses complain about underemployment

Ever found yourself stuck in a hospital bed, pushing that little "help" button and then waiting... waiting... waiting for a nurse? That's when all the headlines about a "nursing shortage" in this country hit home, right?

9 Jul 2012

Cardinal Health to introduce new services for hospitals to leverage outpatient pharmacies

Cardinal Health will this week introduce new services that help hospitals leverage outpatient pharmacies to address two of the their most significant challenges: how to expand the quality care they provide to patients and how to increase revenue.

9 Jul 2012

Positive interim results from Inspiration's OBI-1 Phase 2/3 study for acquired hemophilia A

Inspiration Biopharmaceuticals, Inc. today reported data from its ongoing Phase 2/3 study evaluating the efficacy of OBI-1, an investigational recombinant porcine factor VIII (FVIII), for the treatment of serious bleeds in people with acquired hemophilia A. According to the interim analysis, seven out of seven trial participants receiving OBI-1 experienced control and subsequent resolution of their bleeds.

9 Jul 2012